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HIV-1 Vif inhibits the antiviral activity of APOBEC3G (APO3G) by inducing proteasomal degradation. Here, we studied the effects of Vif on
APO3G in vitro. In this system, Vif did not cause APO3G degradation. Instead, Vif induced changes in APO3G that affected immunoprecipitation
of the native protein. This effect required wt Vif and was reversed by heat denaturation of APO3G. Sucrose gradient analysis demonstrated that wt
Vif induced the gradual transition of APO3G translated in vitro or expressed in HeLa cells from a low molecular mass conformation to
puromycin-sensitive high molecular mass (HMM) complexes. In the absence of Vif or the presence of biologically inactive Vif APO3G failed to
form HMM complexes. Our results expose a novel function of Vif that promotes the assembly of APO3G into presumably packaging-incompetent
HMM complexes and may explain how Vif can overcome the APO3G-imposed block to HIV replication under conditions of no or inefficient
APO3G degradation.
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HIV-1 and most other lentiviruses encode Vif (virion infec-
tivity factor), an accessory protein that is required for virus
replication in primary CD4+ T cells and monocytes. The host
cell factor that inhibits virus replication in the absence of Vif
was identified as APOBEC3G (APO3G) (Sheehy et al., 2002).
APO3G belongs to a family of cytidine deaminases that in
humans include APOBEC1, APOBEC2, seven genes desig-
nated APO3A through APO3H, as well as the activation-
induced deaminase (AID) gene (for a review, see Jarmuz et al.,
2002; Wedekind et al., 2003). In the absence of Vif, APO3G is
active against a broad range of retroviruses but can also block
hepatitis B virus whose replication cycle involves the reverse
transcription of a pregenomic RNA intermediate (Seeger and
Mason, 2000). Recently, another member of the APOBEC⁎ Corresponding author. Fax: +1 301 402 0226.
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doi:10.1016/j.virol.2007.10.017family, APOBEC3F, was shown to inhibit HIV-1 replication by
a mechanism similar to that of APO3G (Wiegand et al., 2004;
Zheng et al., 2004). Interestingly, Vif displays species
specificity in its ability to interact with APO3G and the results
from several independent reports suggest that the determinants
of this species specificity map to amino acid 128 of APO3G
(Bogerd et al., 2004; Mangeat et al., 2004; Schrofelbauer et al.,
2004; Xu et al., 2004). It is now well established that Vif can
reduce the cellular expression of APO3G and inhibit its incor-
poration into virions although the precise mechanism of the
latter activity of Vif is still under investigation (Kao et al.,
2003; Mariani et al., 2003; Marin et al., 2003; Sheehy et al.,
2003; Stopak et al., 2003). The reduction in cellular expression
has been attributed to the degradation of APO3G by
cytoplasmic proteasomes (Conticello et al., 2003; Liu et al.,
2004; Marin et al., 2003; Mehle et al., 2004b; Sheehy et al.,
2003; Stopak et al., 2003; Yu et al., 2003). Based on these
reports, degradation of APO3G involves binding of Vif to
APO3G but also requires the interaction of Vif with components
of an Skp1-cullin-F-box (SCF)-like complex that recognizes a
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(Mehle et al., 2004b; Yu et al., 2003). Other studies, however,
found that Vif can prevent APO3G encapsidation even in the
absence of noticeable degradation suggesting that intracellular
degradation of APO3G may not be the sole mechanism by
which Vif neutralizes its antiviral activity (Kao et al., in
press, 2003, 2004; Mariani et al., 2003; Mehle et al., 2004a;
Opi et al., 2007).
APO3G is a cytoplasmic protein. Immunocytochemistry
revealed diffuse cytoplasmic staining as well as accumulation of
the protein in punctate cytoplasmic structures described as P
bodies or stress bodies (Bogerd et al., 2006; Chen et al., 2006a;
Gallois-Montbrun et al., 2007; Kozak et al., 2006; Niewia-
domska et al., 2007; Opi et al., 2007; Wichroski et al., 2005,
2006). FPLC fractionation of APO3G containing cell lysates
further revealed the assembly of APO3G into high molecular
mass (HMM) complexes (Chen et al., 2006b; Chiu et al., 2005).
Mass spectrometry of immunopurified HMM complexes
identified a multi-subunit ribonucleoprotein complex (Chiu
et al., 2006; Gallois-Montbrun et al., 2007; Kozak et al., 2006).
The formation of high molecular mass complexes is not a
unique property of APOBEC3G but was observed for
APOBEC3F and APOBEC1 as well (Harris et al., 1993;
Wang et al., 2007). Recent data suggest that APO3G antiviral
activity is associated with its low molecular mass conformation
(Kreisberg et al., 2006; Soros et al., 2007). Thus, the functional
significance of HMM APO3G complexes for the control of
retroviral replication remains unclear.
In this study, we have analyzed the effects of Vif on APO3G
in vitro. We employed rabbit reticulocyte lysates to express Vif
and APO3G either alone or in combination and assessed the
impact of Vif on APO3G expression and stability. Rabbit retic-
ulocyte lysates contain all the cellular components necessary for
protein synthesis and post-translational modifications. In
addition, we have previously employed reticulocyte lysates to
investigate the ubiquitin-dependent proteasome degradation of
CD4 (Chen et al., 1993). We found that Vif did not cause deg-
radation of APO3G in our in vitro system. Instead, we found
that binding of wild-type (wt) Vif to APO3G interfered with the
immunoprecipitation of native APO3G by epitope tag-specific
antibodies. This effect was reversed by heat denaturation of
APO3G suggesting an effect of Vif on APO3G conformation.
We hypothesized that wt Vif may induce aggregation of
APO3G into high molecular mass complexes thereby rendering
the protein inaccessible to antibodies for immunoprecipitation.
Indeed, sucrose gradient fractionation of APO3G revealed the
presence of puromycin-sensitive high molecular mass com-
plexes in samples containing wt Vif. APO3G in the absence of
Vif or in the presence of a biologically inactive Vif mutant
failed to form similar high molecular mass complexes.
Importantly, this effect of Vif on APO3G was not only
observed in vitro but was also seen in transfected HeLa cells
suggesting that it is a genuine property of Vif. The results from
this study expose a novel effect of Vif on APO3G that does not
require protein degradation and thus has important implications
for our understanding of the role of Vif in the inhibition of
APO3G antiviral activity.Results
In vitro interaction of Vif and APO3G
Co-immunoprecipitation studies performed in tissue culture
previously demonstrated physical interactions between Vif and
APO3G (Bogerd et al., 2004; Conticello et al., 2003; Mangeat
et al., 2004; Mariani et al., 2003; Marin et al., 2003; Stopak
et al., 2003; Xu et al., 2004; Yu et al., 2003). To further study
functional interactions of Vif and APO3G, we employed an in
vitro transcription/translation system where Vif and APO3G
genes were separately transcribed using SP6 RNA polymerase
and the resulting mRNAwas used to direct protein synthesis in
rabbit reticulocyte lysates. Our first goal was to verify that Vif
and APO3G physically interacted in this in vitro system. To that
end, we translated wild-type (wt) Vif or a Vif mutant unable to
inhibit the antiviral activity of APO3G (VifΔ23–43; Khan et al.,
2001) as well as APO3G-MycHis in separate translation reac-
tions. A mock reaction without mRNAwas prepared in parallel.
The two Vif proteins were metabolically labeled with [35S]
methionine/cysteine whereas APO3G and the mock sample
remained unlabeled. The translation reactions were stopped
after 60 min and lysates containing APO3G and either wt Vif or
VifΔ23–43 were mixed at 1:1 ratios (20 μl each), supplemented
with fresh lysate to a total volume of 150 μl and 50 μl each were
incubated at 30 °C for 0, 15, or 45 min. Similarly, mock lysates
were mixed with lysates containing wt Vif or VifΔ23–43 and
processed in the same manner. Samples were either analyzed
directly by SDS-PAGE (Fig. 1, total protein) or subjected to
immunoprecipitation with a polyclonal antibody to the Myc
epitope tag present at the C-terminus of APO3G (Fig. 1, IP). As
expected, Vif was not precipitated by the Myc-specific antibody
in the absence of APO3G (Fig. 1, lanes 1–3 and 7–9). In
contrast, wt Vif and VifΔ23–43 co-precipitated with APO3G
(Fig. 1, lanes 4–6 and 10–12, respectively). These results
confirm that Vif and APO3G are able to interact in vitro and that
deletion of residues 23–43 in Vif did not affect its ability to
interact with APO3G. Interestingly, preincubation of Vif with
APO3G containing lysates failed to improve co-immunopre-
cipitation of wt Vif or VifΔ23–43 suggesting that Vif:APO3G
complexes in both cases formed rapidly after mixing the
samples.
Wt Vif affects immunorecogniton of APO3G
To analyze possible effects of Vif on APO3G stability in
vitro, a time-course experiment was performed. To that end, Vif
and APO3G were individually translated in reticulocyte lysates.
In this case, APO3G protein was labeled with [35S] methionine/
cysteine whereas Vif proteins were synthesized in the absence
of isotope. The translation reactions were stopped after 60 min,
at which time Vif- and APO3G-containing lysates were mixed
at 1:1 ratios (20 μl each) and fresh reticulocyte lysate was added
to a total volume of 250 μl. The reaction mixture was instantly
redistributed into 5 equal aliquots of 50 μl each, which were
then incubated for up to 3 h at 30 °C. Individual aliquots were
removed at different time points as indicated in Fig. 2 and stored
Fig. 1. In vitro interaction of Vif and APO3G. In vitro transcription plasmids encoding wt Vif, VifΔ23–43, and human APO3G were linearized at their 3′ ends
followed by in vitro transcription and translation in rabbit reticulocyte lysates as described in Materials and methods. The translation reaction was allowed for 60 min at
30 °C and then stopped by addition of RNase A (50 μg/ml). Vif proteins were synthesized in the presence of [35S] methionine/cysteine. APO3G protein and mock
samples were not metabolically labeled. Vif-containing lysates were mixed at equal ratios with either mock lysate (mock) or APO3G-containing lysate (APO3G).
Samples were divided into equal fractions and incubated for 0, 15, or 45 min at 30 °C. An aliquot of each sample (20%) was analyzed directly after TCA precipitation
(total protein). The remaining samples (80%) were immunoprecipitated with a polyclonal Myc antibody (lower panel). Note that only Vif proteins are visible since
APO3G was unlabeled. The positions of wt Vif and VifΔ23–43 in the gel are indicated on the right.
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total) from each time point were then either TCA precipitated
(Fig. 2A, TCA) or immunoprecipitated (80% of each sample)
using a polyclonal antibody against the Myc epitope tag of
APO3G (Fig. 2A, IP). APO3G-specific bands were quantified
and results from four independent experiments were plotted as
percentage of the starting material (Fig. 2B). We found that
incubation of wt Vif with APO3G did not have any discernible
effects on the stability of APO3G over the 3-h observation
period as evidenced by the fact that the amounts of total protein
did not decrease with time (Fig. 2B, open circles). Surprisingly,
however, there was a gradual decrease in the amount of APO3G
immunoprecipitated by the antibody to the Myc epitope tag.
Quantitation of the APO3G-specific bands (Fig. 2B, closed
circles) showed that the amounts of APO3G recovered by
immunoprecipitation rapidly decreased with a “half-life” of
about 90 min. The reduction in immunoprecipitated APO3G
cannot be explained by Vif-induced degradation of the protein
since direct protein analysis (Fig. 2B, open circles) clearly
verified the presence of constant amounts of APO3G at all
times. This conclusion is further supported by our observation
that the presence of 50 μM MG132 during the 3-h incubation
period did not prohibit the gradual loss of immunorecognition
of APO3G (Fig. S1). The reduced immunoprecipitation of
APO3G can also not be explained by proteolytic removal of the
Myc epitope tag since the resulting shift in the mobility of the
protein would be apparent in Fig. 2A. Thus, the most plausible
explanation for the progressively reduced immunoprecipitation
of APO3G by the Myc-specific antibody is direct or indirect
interference by Vif. Of note, the observed effects were epitope
tag-independent since similar results were obtained with HA-
tagged APO3G (data not shown).
A biologically inactive Vif mutant does not interfere with
immunorecognition of APO3G
In Fig. 1 we demonstrated the ability of Vif to interact with
APO3G in vitro. This raised the possibility that the reducedimmunoprecipitation of APO3G in Fig. 2A was the result of
steric interference by Vif. To address this issue, we performed a
kinetic study of APO3G in the presence of the VifΔ23–43
variant, which is biologically inactive (Khan et al., 2001) but
still capable of binding to APO3G in vitro (Fig. 1). The
experimental procedure and quantitation of the results were the
same as described for Figs. 2A and B. Consistent with the
results from Fig. 2A, direct analysis of APO3G protein did not
reveal any effects of VifΔ23–43 on APO3G stability (Fig. 2C,
TCA). Interestingly, constant amounts of APO3G were
recovered at all times by immunoprecipitation (Fig. 2C, IP)
and quantitation of the data confirmed that VifΔ23–43 did not
affect immunorecognition of APO3G (Fig. 2D). The different
effects of wt Vif and VifΔ23–43 on the immunoprecipitation of
APO3G are difficult to explain by steric interference of Vif with
Myc antibody binding to its target epitope since both wt Vif and
VifΔ23–43 interacted with APO3G (Fig. 1). Our finding that
VifΔ23–43 had no effect on APO3G immunoprecipitation also
suggests that the increasing resistance of APO3G to immuno-
precipitation in Fig. 2A was not the result of normal post-
translational protein refolding but was caused by the addition of
wt Vif to the sample.
As an additional control for the specificity of the effect of
HIV-1 Vif on human APO3G, we analyzed the impact of HIV-1
Vif on African Green monkey APO3G (Agm-APO3G), which
is resistant to HIV-1 Vif (Bogerd et al., 2004; Mangeat et al.,
2004; Mariani et al., 2003; Schrofelbauer et al., 2004). The
experiment was performed essentially as described for Figs.
2A and B employing wild-type HIV-1 Vif and Agm-APO3G
and the results are shown in Fig. S2. As expected, Vif had no
effect on the stability of Agm-APO3G as judged by direct
protein analysis (Fig. S2B, open circles). Importantly, wild-
type HIV-1 Vif also had no effect on the immunoprecipitation
of Agm-APO3G (Fig. S2B, closed circles). Thus, the effect of
wild-type HIV-1 Vif on the conformation of native human
APO3G observed in Fig. 2 is highly specific and dependent
on the direct interaction of wild-type HIV-1 Vif with human
APO3G.
Fig. 2. Post-translational effect of Vif on APO3G in vitro. Vif (unlabeled) and APO3G ([35S]-methionine/cysteine-labeled) were translated separately in reticulocyte
lysate for 60 min at 30 °C. Equal amounts of the lysates were mixed and fresh reticulocyte lysate was added to a total volume of 250 μl. The mixture was immediately
divided into 5 samples (50 μl each), which were then incubated for 0, 15, 45, 90, or 180min at 30 °C. (A and B) Analysis of wt Vif. (A) For total protein analysis, 20% of
the samples from each time point was precipitated with TCA and subjected to SDS-PAGE (top panel). Remaining samples (80%) were immunoprecipitated using a
polyclonal Myc antibody prior to SDS-PAGE (lower panel). (B) The APO3G-specific bands from panel Awere quantitated using a Fuji BAS 2000 Bio-Image Analyzer
and the results were plotted as a function of time. Error bars reflect standard error from four independent experiments. (C andD)Analysis of VifΔ23–43. The experiment
is identical to panels A and B except that VifΔ23–43was employed instead of wt Vif. Error bars reflect standard error from four independent experiments. (E and F) Heat
denaturation rescues immunoprecipitation of APO3G exposed to wt Vif. (E) The experiment was done essentially as described for panels A and B. For total protein
analysis, 20% of the samples from each time point was precipitated with TCA and subjected to SDS-PAGE (top panel). The remaining samples (80%) were divided into
2 equal parts. One half was immunoprecipitated using a polyclonal Myc antibody as in panel A. The second half was first denatured by adding an equal volume of 2×
sample buffer and heating the sample at 95 °C for 5 min. Prior to immunoprecipitation, the sample volume was increased to 1 ml using phosphate-buffered saline to
reduce detergent and 2-mercaptoethanol levels in the sample. Immunoprecipitation was then carried out as before at 4 °C using a polyclonalMyc antibody (lower panel).
(F) The APO3G-specific bands from panel E were quantitated as in panel B. Error bars reflect standard error from two independent experiments.
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To test if the inaccessibility of APO3G to immunoprecipi-
tation in Fig. 2A was due to a Vif-induced change in APO3G
conformation, we subjected APO3G that had previously been
exposed to wt Vif to heat denaturation prior to immunoprecip-
itation. The experiment was essentially performed as described
for Fig. 2A except that prior to immunoprecipitation by theMyc-
specific polyclonal antibody, half of the APO3G sample was
heated for 5 min at 95 °C as detailed in the legend to Fig. 2. The
results of the experiment are shown in Fig. 2E and the
quantitative analysis of two independent experiments is shownin Fig. 2F. As expected, direct analysis of TCA precipitated
protein confirmed the presence of constant amounts of APO3G
throughout the 3-h observation period (Fig. 2F, closed triangles).
Also, immunoprecipitation of non-denatured protein revealed
the same gradual loss of APO3G as observed in Fig. 2A (Fig. 2F,
closed circles). Importantly, however, heat denaturation of the
protein samples prior to immunoprecipitation led to the recovery
of similar amounts of APO3G by immunoprecipitation at all
time points (Fig. 2F, open circles). These results support our
model that interaction of wt Vif with APO3G induces a gradual
yet reversible conformational change that affects APO3G
recognition by epitope tag-specific antibodies.
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Tissue culture analyses have identified APO3G in two prin-
cipal conformations: a low molecular mass (LMM) conformation
of cytoplasmic APO3G and a high molecular mass (HMM)
conformation, in which APO3G is associated with a variety of
other host factors in a large RNA–protein complex in P bodies or
stress granules (Chiu et al., 2005; Gallois-Montbrun et al., 2007;
Kozak et al., 2006; Wichroski et al., 2006). Newly synthesized
APO3G is initially in the LMM conformation but assembles into
HMM multi-protein complexes within approximately 30 min
after synthesis (Soros et al., 2007). While this change of APO3G
from LMM to HMM conformation is a natural process that does
not require Vif, it is conceivable that the presence ofVif affects the
kinetics of APO3G transition from LMM to HMM conformation.
We next studied the possible effects of Vif on APO3G
conformation in our in vitro system. In this experiment, APO3G
was metabolically labeled with [35S] methionine/cysteine
whereas wt Vif and VifΔ23–43 were translated in the absence
of isotope as described for Fig. 2. In vitro synthesized [35S]-
labeled APO3G was incubated for 3 h at 30 °C with mock-
translated lysate (Fig. 3A, top panel), lysate containing wt Vif
(Fig. 3A, middle panel), or lysate containing VifΔ23–43 (Fig.
3A, lower panel). Samples were then layered onto a 15–40%
sucrose gradient and centrifuged at 86,000×g for 3 h as reported
(Kozak et al., 2006). Fractions were collected from the top of the
gradient and subjected to 12.5% SDS PAGE. Fraction #1 was
omitted from the analysis because it contained residual
unincorporated isotope. APO3G proteins were visualized by
fluorography. In the absence of Vif (Fig. 3A, top panel) or in the
presence of VifΔ23–43 (Fig. 3A, bottom panel), APO3G wasFig. 3. Sucrose gradient analysis of in vitro translated APO3G. (A) In vitro synthesi
volume of mock-translated lysate (top panel) or with an equal volume of lysate co
incubation, the samples were layered onto 10 ml gradients of 15–40% sucrose in buff
and centrifuged for 3 h at 86,000×g. Nineteen fractions (530 μl each) were collecte
Aliquots were separated by SDS-12.5% PAGE and APO3G protein was visualized by
now metabolically labeled and APO3G remained unlabeled. The mock-translated co
Sucrose gradient analysis and gel electrophoresis were performed as in panel A.confined to the top of the gradient (fractions 2–6). In contrast,
the presence of wt Vif resulted in a broader distribution of
APO3G across the sucrose gradient (Fig. 3A, middle panel) and,
in addition, small amounts of APO3G were recovered from the
bottom of the gradient (fraction 19). Analysis of Vif in an
experiment identical to the one shown in Fig. 3A except that Vif
was metabolically labeled and APO3G remained unlabeled
showed that Vif was largely confined to the upper fractions (Fig.
3B, fractions 2–8). We conclude that the presence of wt Vif
promotes the assembly of APO3G into HMM complexes in
vitro. The formation of in vitro APO3G HMM complexes was
detergent-sensitive and complexes could be dissociated by
addition of 0.5% SDS (data not shown).
Vif induces APO3G transition complexes
We next studied the kinetics of Vif-induced formation of
HMM APO3G complexes in vitro. The experiment was
performed essentially as described for Fig. 3A except that Vif
and APO3G were incubated for various times (30 min, 90 min,
180 min) prior to sucrose gradient centrifugation (Fig. 4). At all
times, significant amounts of APO3G were found in the upper
fractions of the gradient (Fig. 4, all panels, fractions 2–4).
Interestingly, an intermediate APO3G complex was detectable
at the 30-min and 90-min time points (Fig. 4, fraction 14; top
and middle panels) but was absent from the 180-min sample. At
the same time, APO3G in fraction 19 was undetectable in the
30-min sample (Fig. 4, top panel, fraction 19) but was identified
in increasing amounts in the later samples (Fig. 4, middle and
lower panels, fraction 19). We conclude that conversion of
APO3G from LMM to HMM conformation in vitro in thezed [35S]-labeled APO3G (20 μl) was incubated for 3 h at 30 °C with an equal
ntaining unlabeled wt Vif (middle panel) or Vif Δ23–43 (lower panel). After
er B (0.01 M Tris–Cl, pH 7.4, 0.25 M KCl, 0.01 MMgCl2 (Kozak et al., 2006))
d from the top of the gradient and combined with 175 μl of 4× sample buffer.
fluorography. (B) The experiment was repeated as in panel A except that Vif was
ntrol was omitted here since no labeled protein was present in the mock lysate.
Fig. 4. Kinetic analysis of APO3G high molecular mass complexes. In vitro synthesized [35S]-labeled APO3G (20 μl) was incubated for 30, 90, or 180 min at 30 °C
with an equal volume of lysate containing unlabeled wt Vif. Samples were either incubated alone (untreated) or in the presence of puromycin (0.5 μg/ml; puromycin).
After incubation, the samples were layered onto 10 ml gradients of 15–40% sucrose and processed as in Fig. 3A.
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formation of a distinct transition complex.
Recently, Kozak et al. (2006) found that APO3G complexes
from transfected 293T cells were sensitive to treatment with
puromycin, a drug known to induce the release of nascent
proteins from polysomes; their results strongly suggested that
APO3G in untreated samples was bound to translationally
active polysomes. Interestingly, when puromycin was added to
our in vitro reactions, the Vif-induced assembly of APO3G into
intermediate (fraction 14) and heavy complexes (fraction 19)
was completely inhibited as well (Fig. 4, puromycin). Thus, it
appears that Vif promotes the association of APO3G with
polysomes in vitro.
In Fig. 3B we demonstrated that Vif was not part of the heavy
APO3G complexes even though the formation of these
complexes was Vif-dependent. To see if Vif was part of the
APO3G transition complexes identified in Fig. 4 we metabol-
ically labeled both Vif and APO3G and incubated the combined
lysates for 30 or 90 min as described for Fig. 4. Samples were
then subjected to sucrose gradient analysis as in Fig. 4. For
comparison we analyzed APO3G in combination with either wt
Vif (Fig. 5A) or VifΔ23–43 (Fig. 5B). In this experiment both
APO3G and Vif are visible (Fig. 5). As expected, APO3G
formed a distinct transition complex in the presence of wt Vif
(Fig. 5A, APO3G) following 30- or 90-min incubation.
Interestingly, wt Vif was found in fractions of the gradient up
to and including fraction 14 (Fig. 5A, wt Vif). Consistent with
our previous results, no transition complexes were observed in
the presence of VifΔ23–43 and both VifΔ23–43 and APO3G
were restricted to fractions 1–10 of the sucrose gradient
(Fig. 5B). These results suggest that Vif may be part of APO3G
transition complexes but subsequently dissociates as APO3G
continues to form increasingly heavy complexes pelleting to the
bottom of our gradients.Effect of Vif on HMM association of APO3G in transfected
HeLa cells
We recently identified an APO3G variant, APO3G-C97A,
which was resistant to Vif-induced degradation but was still
sensitive to Vif with respect to virus incorporation and antiviral
activity (Opi et al., 2007). We also found that the ability of Vif to
exclude APO3G from virions could be dissociated from its
ability to cause proteasomal degradation of APO3G (Kao et al.,
in press). From these observations we concluded that Vif had
the ability to regulate APO3G encapsidation through degrada-
tion-independent mechanism(s). Furthermore, Soros et al.
(2007) recently provided evidence that virus encapsidated
APO3G is derived primarily from the LMM pool of de novo
synthesized protein. Thus, the ability of Vif to promote the
transition of APO3G from an LMM to a HMM conformation
could be a way to prevent encapsidation of APO3G into HIV-1
virions in the absence of protein degradation.
To study the effect of Vif on HMM association of APO3G in
tissue culture, HeLa cells were transfected with pcDNA-APO3G
together with either pNL-A1 for the expression of Vif (Fig. 6A)
or pNL-A1vif(−) as a vif-negative control (Fig. 6B). To prevent
Vif-induced degradation of APO3G, a dominant negative Cul5
mutant, Cul5-Rbx (Yu et al., 2003), was cotransfected in this
experiment. Cells were harvested 24 h later and lysed as
described in Materials and methods. Post-nuclear extracts were
overlaid onto 15–40% sucrose gradients and centrifuged for 3 h
at 86,000×g. Twenty fractions (500 μl each) were collected from
the top of the gradients and subjected to immunoblot analysis
using an APO3G-specific peptide antibody (Figs. 6A and B, α-
APO3G). The same blots were subsequently re-probed with a
Vif-specific monoclonal antibody (α-Vif). In general, APO3G
from transfected HeLa cells was more broadly distributed in the
gradient than in vitro translated APO3G. This suggests that in
Fig. 5. Association of Vif with APO3G complexes. In vitro synthesized [35S]-labeled APO3G (20 μl) was incubated for 30, 90, or 180 min at 30 °C with an equal
volume of lysate containing [35S]-labeled wt Vif (A) or VifΔ23–43 (B). After incubation, the samples were layered onto 10 ml gradients of 15–40% sucrose and
processed as in Fig. 3A.
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assembly into HMM complexes irrespective of the presence or
absence of Vif. Interestingly, the co-expression of Vif resulted inFig. 6. Vif promotes HMM complex formation of APO3G in transfected HeLa cells. H
Rbx DNA and 2 μg of either pNL-A1 DNA (A) or pNL-A1vif(−) DNA (B). Cells
(5 min, 4 °C). Nuclei were pelleted (1500×g, 5 min), the post-nuclear supernatant
centrifuged for 3 h at 86,000×g. Twenty fractions (500 μl each) were collected from
using an APO3G-specific antibody (α-APO3G). The same blots were then re-probethe appearance of a heavy APO3G complex sedimenting to the
bottom of the sucrose gradient thus closely mimicking our in
vitro results (Fig. 6A, fraction #20). This complex was not seeneLa cells were transfected with pcDNA-APO3G (3 μg), together 1 μg of pCul5-
were harvested 24 h after transfection and lysed in 400 μl of NP40 lysis buffer
s were overlaid onto a 15–40% sucrose gradient as described for Fig. 3, and
the top of the gradient and indicated fractions were analyzed by immunoblotting
d with a Vif-specific monoclonal antibody (α-Vif).
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analyses, Vif was absent from the heavy APO3G complexes
(Fig. 6A, α-Vif). Our results suggest that the ability of Vif to
promote the transition of APO3G from light to heavy complexes
is not limited to the in vitro system but can be observed in tissue
culture systems as well and is therefore likely to represent a
functionally relevant property of Vif.
Discussion
HIV-1 Vif is essential for replication in vivo and in non-
permissive cell types in tissue culture. Several recent studies
have reported that Vif can induce the degradation of APO3G
when expressed in non-permissive target cells. This effect of Vif
is manifested by a reduction of the half-life of APO3G in the
presence of Vif when compared to vif-deficient controls
(Conticello et al., 2003; Liu et al., 2004; Marin et al., 2003;
Mehle et al., 2004b; Sheehy et al., 2003; Stopak et al., 2003; Yu
et al., 2003). Furthermore, the decrease in APO3G protein levels
was abrogated in the presence of proteasome inhibitors, indi-
cating that Vif targeted APO3G for degradation by proteasomes
(Conticello et al., 2003; Liu et al., 2004; Marin et al., 2003;
Mehle et al., 2004b; Sheehy et al., 2003; Stopak et al., 2003; Yu
et al., 2003). In support of this hypothesis, co-expression of Vif
and APO3G was shown to result in poly-ubiquitination of
APO3G, which is known to precede the proteasome-dependent
degradation of proteins (for a review, see Ciechanover et al.,
2000). Indeed, Yu et al. (2003) demonstrated that Vif interacts
with components of an ubiquitin ligase complex through a
conserved motif near the C-terminus of Vif providing additional
evidence that Vif regulates the degradation of APO3G. Thus,
there is overwhelming evidence that Vif can induce the deg-
radation of APO3G in tissue culture systems.
On the other hand, we and others have found that inhibition of
APO3G encapsidation by Vif is not always accompanied by a
proportional reduction in cellular APO3G (Kao et al., in press,
2003, 2004;Mariani et al., 2003) and, more importantly, we have
recently identified an APO3G variant that was resistant to Vif-
induced degradation but was nonetheless excluded from HIV-1
virions in a Vif-dependent manner (Opi et al., 2007). Thus, there
is increasing evidence that Vif can prevent encapsidation of
APO3G not only through targeting the protein to a proteasomal
degradation pathway but through additional as yet undefined
mechanism(s).
Our in vitro study was initiated by the desire to further study
the mechanism of Vif-induced degradation of APO3G. We were
encouraged in choosing an in vitro system by our previous
success in demonstrating proteasome-mediated degradation of
CD4 in the presence of Vpu in rabbit reticulocyte lysates (Chen
et al., 1993). A significant advantage of the in vitro system was
that proteins could be analyzed directly without prior immuno-
precipitation since de novo synthesis of metabolically labeled
proteins was strictly limited to exogenously supplied mRNA.
Our initial immunoprecipitation analyses indeed revealed a
gradual decrease of APO3G with time and produced kinetic
profiles suggestive of protein degradation (Fig. 2B). However,
direct analysis of TCA-precipitated, in vitro translated proteinsrevealed that the reduced APO3G signals in the immunopreci-
pitates were not due to protein degradation but rather reflected an
effect of Vif on APO3G that induced a gradual resistance to
immunoprecipitation. In fact, APO3G protein was perfectly
stable over the 3-h observation period irrespective of the pres-
ence of wt or mutant Vif protein. It is not clear why Vif was
unable to induce APO3G degradation in vitro. However, our
previous in vitro studies on Vpu-induced degradation of CD4
employed lysates that had been supplemented with canine
microsomal membranes (Chen et al., 1993). It is possible that
these membrane preparations contributed factors crucial to pro-
teasomal protein degradation. However, this was not further
explored in the current study.
Instead, we used the fact that Vif did not cause degradation of
APO3G in vitro as an opportunity to study additional
degradation-independent effects of Vif on APO3G. Indeed,
our in vitro study provided evidence that Vif may promote the
sequestration of APO3G into packaging-incompetent HMM
complexes. This conclusion was supported by our finding that
the presence of Vif induced changes in APO3G that rendered the
protein progressively less available to immunoprecipitation.
This trend could be reversed by heat denaturation of APO3G
prior to immunoprecipitation suggesting that wt Vif induced
heat-labile changes in APO3G. Sucrose gradient analyses
subsequently showed that the presence of wt Vif was associated
with the transition of APO3G into high molecular mass com-
plexes (Figs. 3–5). These effects were specific for wt Vif and
were not observed with a biologically inactive Vif mutant
(Fig. 3A, bottom panel). From the data shown in Fig. 3A it
appears that only a small fraction of the total APO3G assembled
into heavy complexes while in Fig. 2 the majority of APO3G
appears to become resistant to immunoprecipitation. This does
not rule out a functional correlation between the two effects since
it is possible that subjecting the samples to sucrose gradient
centrifugation causes partial dissociation of the complexes. This
is suggested by our finding that a significant amount of APO3G
from transfected HeLa cells is identified in the upper (low
molecular mass) fractions in the sucrose gradient shown in
Fig. 6, while FPLC analyses identified the majority of APO3G
from transfected HeLa cells in HMM complexes (Opi et al.,
2007). Thus, we believe that the gradual transition from a low
molecular mass to a high molecular mass conformation of
APO3G most likely accounts for its increasing resistance to
immunoprecipitation as observed in Fig. 2.
How Vif might promote the transition of APO3G from LMM
to HMM conformations remains to be investigated. Both wt Vif
and VifΔ23–43 interacted with APO3G in our in vitro analyses.
In fact, VifΔ23–43 appeared to interact slightly more efficiently
with APO3G than wt Vif (Fig. 1). These results are consistent
with co-immunoprecipitation studies in HeLa cells that revealed
solid binding of VifΔ23–43 to APO3G (data not shown).
Interestingly, the interaction of Vif and APO3G was not
improved by preincubating the proteins at 30 °C. This suggested
that binding of Vif to APO3G was a rapid process. The rapid
binding of Vif to APO3G contrasts the slow and gradual in-
creasing resistance of APO3G to immunoprecipitation as shown
in Fig. 2. These kinetic differences argue against steric
144 R. Goila-Gaur et al. / Virology 372 (2008) 136–146interference by Vif with antibody binding. Instead they suggest
that the resistance of APO3G to immunoprecipitation is due to
the conversion of APO3G from a low molecular mass to a high
molecular mass conformation.Why only wt Vif can induce these
changes is unclear. Both Vif and APO3G are nucleic acid
binding proteins and APO3G HMM complexes were previously
found to be sensitive to RNase treatment (Chiu et al., 2005;
Gallois-Montbrun et al., 2007; Kozak et al., 2006; Opi et al.,
2007; Wang et al., 2007). Of note, rabbit reticulocyte lysates
used in this study had been treated with micrococcal nuclease
and our in vitro translation reactions were routinely stopped by
the addition of RNase A. Nevertheless, it is possible that APO3G
or Vif mRNAs used for the in vitro translations were protected
from complete RNase digestion and it is possible that the in vitro
HMM APO3G complexes represent RNA–protein complexes
similar to those observed in vivo. In support of this we found that
the APO3G complexes dissociated in the presence of puromycin
suggesting that they involved noncovalent interactions of
APO3G and polysomes. We therefore propose a model, in
which APO3G forms a complex with polysomes in reticulocyte
lysates similar to those reported in transfected 293Tcells (Kozak
et al., 2006; Niewiadomska et al., 2007). We speculate that these
Vif induced APO3G-polysome complexes are resistant to
immunoprecipitation presumably because the C-terminal epi-
tope tag on APO3G is inaccessible to antibodies in these
complexes. Importantly, we were able to demonstrate Vif-
induced heavy complexes of APO3G in HeLa cells (Fig. 6) and
we observed gradual resistance of APO3G in transfected HeLa
cells to immunoprecipitation by conformation-sensitive anti-
bodies (data not shown). We therefore conclude that the effects
of Vif on APO3G conformation described in this study reflect a
process occurring in vitro as well as in vivo.
Taken together our results provide evidence for a novel
function of Vif that is likely to contribute to the exclusion of
APO3G from viral particles by sequestering the protein in
packaging-incompetent high molecular mass intracellular com-
plexes. Such a function of Vif could be important early in
infection when APO3G has not yet been eliminated from virus-
producing cells by proteasome-mediated protein degradation.
Materials and methods
Plasmids
The in vitro transcription vector pSP65 (Promega Bios-
ciences, San Luis Obispo, CA) was used for expression of vif
and APO3G genes under the control of the SP6 promoter. For the
expression of wt Vif, HIV-1 vifwas PCR amplified from pNL4-3
and cloned as an EcoRI/BamHI fragment into pSP65 (Chen
et al., 1993) resulting in vector pSP-Vif. For the expression of
VifΔ23–43, the mutant vif gene was PCR amplified from pNL-
A1/VifΔ23–43 (Khan et al., 2001) and cloned between the
EcoRI/BamHI sites of pSP65 resulting in pSP-VifΔ23–43. For
expression of human APO3G, pSP-hAPO3G was constructed
by subcloningAPO3G including its C-terminalMyc-His epitope
tag from pcDNA-APO3G (Kao et al., 2003) into the pSP65
vector via its EcoRI and XbaI cloning sites. The followingplasmids were used for expression in HeLa cells: pcDNA-
APO3G for the expression of untagged human wt APO3G;
pNL-A1 for the expression of Vif (Strebel et al., 1987); and
pNL-A1vif(−) as a vif-negative control (Karczewski and
Strebel, 1996). Plasmid pCul5-HA was a gift of Xiao-Fang Yu
(Yu et al., 2003). An Rbx binding mutant, pCul5-Rbx-HA, was
constructed by deleting residues 566–582 in pCul5-HA as
described (Yu et al., 2003). The vector pSP-AgmAPO3G was
used for expression of Agm-APO3G. This vector was con-
structed by subcloning Agm-APO3G including its C-terminal
HA tag from pc-AGM-APO3G-HA (gift of Ned Landau) into
pSP65.
Antisera
Immunoprecipitation of APO3G was carried out using a
polyclonal antibody to the C-terminal Myc epitope tag (Sigma-
Aldrich, St. Louis, MO). For immunoprecipitation of Agm-
APO3G a rat monoclonal antibody to its C-terminal HA tag was
used (Roche Diagnostics, Indianapolis, IN). A monoclonal
antibody to Vif (MAb #319) was used for immunoblot analysis
of Vif and was obtained from Michael Malim through the NIH
AIDS Research and Reference Reagent Program (Simon et al.,
1995). APO3G was identified using a rabbit polyclonal peptide
antibody (ApoC17 (Opi et al., 2007)).
In vitro transcription and translation
For the in vitro synthesis of run-off transcripts, all plasmids
were initially linearized at the 3′ end of the coding sequences
using appropriate restriction enzymes. Plasmids pSP-Vif and
pSP-VifΔ23–43 were linearized with BamHI whereas pSP-
APO3G was linearized using XbaI. Subsequent in vitro tran-
scription of the linearized DNAwas performed using an in vitro
transcription kit (SP6 Riboprobe system; Promega Biosciences)
according to the manufacturer's instructions. RNA resulting
from the transcription of 1 μg of plasmid DNAwas suspended in
50 μl of RNase-free water. In vitro transcribed RNAwas used to
direct the in vitro translation of proteins in rabbit reticulocyte
lysates. Typically, 5 μl of RNAwas mixed with 40 μl of rabbit
reticulocyte lysate (Promega Biosciences) in the presence or
absence of 10 μl of [35S] methionine/cysteine (Redivue Pro Mix
(10 mCi/ml); Amersham Biosciences Piscataway, NJ) and
incubated for 60 min at 30 °C. Translation reactions were
terminated by addition of RNase A (50 μg/ml) to the samples.
Proteins were then either subjected to immunoprecipitation or
directly analyzed by TCA precipitation and SDS-PAGE.
TCA precipitation and immunoprecipitation
For direct analysis of in vitro translated proteins, proteins
were precipitated with trichloroacetic acid (TCA) prior to gel
electrophoresis to remove unincorporated isotope. For that
purpose, 50 μl of cold 25% TCA was added to 10 μl of
translation mix while vortexing. The sample was then incubated
on ice for 10 min followed by a brief spin in an Eppendorf
microcentrifuge (10 s, 14,000×g) to pellet protein aggregates.
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carded and the pellet was washed twice with cold 2% TCA. The
pellet was finally suspended in 100 μl of sample buffer (2%
SDS, 1% β-mercaptoethanol, 1% glycerol, and 65 mM Tris–
hydrochloride (pH 6.8)) and neutralized by addition of 1 N
NaOH. The samples were boiled for 5 min and loaded onto
12.5% polyacrylamide-SDS gels.
Immunoprecipitation of in vitro translated proteins was
carried out using appropriate antibodies as described in the text.
Briefly, polyclonal antibodies to the Myc epitope or to Vif
(Vif93) were adsorbed on protein A sepharose beads (Sigma-
Aldrich) whereas rat anti-HA antibodies were adsorbed on
protein G sepharose beads (Amersham) for 1 h at 4 °C on a
rotating wheel. The beads were then washed once with cold
Triton-Wash Buffer (50 mM Tris pH 7.4, 300 mM NaCl, 0.1%
Triton X-100). Antibody-adsorbed beads were then suspended
in 1 ml of cold 0.1% BSA/PBS, 40 μl of translation reaction mix
was added and beads were incubated for 1 additional h at 4 °C
on a rotating wheel. After incubation, the beads were washed 3
times with 750 μl of Triton-Wash Buffer. Bound proteins were
solubilized by boiling the beads in 100 μl of sample buffer and
were then separated on 12.5% polyacrylamide-SDS gels. Gels
were soaked in 1 M sodium salicylic acid for 30 min and dried.
Radioactive bands were visualized by fluorography. Quantita-
tion of the radioactivity of the respective bands was performed
with a Fuji BAS 2000 Bio-Image Analyzer.
Immunoblotting
For immunoblot analysis of sucrose gradient fractions, 75 μl
of each fraction was combined with 25 μl of 4× sample buffer
(8% sodium dodecyl sulfate, 250 mM Tris–HCl, pH 6.8, 20%
2-mercaptoethanol, 20% glycerol). Proteins were heated for 10
to 15 min at 95 °C with occasional vortexing of the samples
prior to SDS-PAGE; proteins were transferred to PVDF
membranes and reacted with appropriate antibodies as de-
scribed in the text. Membranes were then incubated with
horseradish peroxidase-conjugated secondary antibodies
(Amersham Biosciences, Piscataway, NJ) and visualized by
enhanced chemiluminescence (ECL, Amersham Biosciences).
Sucrose gradient fractionation
For the analysis of in vitro synthesized APO3G, lysates were
incubated for different times with lysates containing either wt
Vif or the Vif Δ23–43 mutant. After incubation, the samples
were layered over 10 ml of 15–40% sucrose gradients made in
buffer B (0.01 M Tris–Cl, pH 7.4, 0.25 M KCl, 0.01 M MgCl2)
and centrifuged at 86,000×g for 3 h (Kozak et al., 2006). For the
analysis of APO3G complexes in HeLa cells, transfected cells
were lysed on ice in 400 μl of NP40 lysis buffer (50 mM Tris–
HCl pH 7.4, 1% NP40, 0.1% deoxycholate (DOC), 150 mM
NaCl, and protease inhibitor cocktail). Nuclei were removed by
centrifugation for 5 min at 1500×g. Post-nuclear extracts were
overlaid onto a 15–40% sucrose gradient and centrifuged for
3 h at 86,000×g (Kozak et al., 2006). Nineteen to twenty
fractions were collected from the top of the gradient and thesamples were combined with 175 μl 4× sample buffer and
heated for 5 min at 95 °C. Aliquots of each fraction were loaded
on 12.5% SDS-PAGE gels. For the analysis of [35S]-labeled in
vitro translated proteins, gels were soaked in 1 M sodium
salicylic acid for 30 min and dried. Radioactive bands were
visualized by fluorography. Quantitation of the radioactivity of
the respective bands was performed with a Fuji BAS 2000 Bio-
Image Analyzer. Proteins from HeLa extracts were analyzed by
immunoblotting.
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